Expression of Concern: Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort (2026)

Peer-Reviewed Study · Editorial Board, Anticancer Research · June 9, 2026

Editorial Board et al., 2026-06-09: Expression of concern opening a post-publication data-integrity and ethical-oversight audit of the 197-patient cohort, citing concerns about verifiability, statistical reliability and ethics review.

Following publication, serious scientific concerns were raised by the international medical community regarding the verifiability and statistical reliability, and ethical oversight of the underlying dataset.

Editorial Board et al., 2026-06-09: Expression of concern opening a post-publication data-integrity and ethical-oversight audit of the 197-patient cohort, citing concerns about verifiability, statistical reliability and ethics review. C5. Record of the journal's first action on the paper: the board wrote that a study reporting 'a Clinical Benefit Ratio of 84.4%' and specific percentages of 'tumor regression' 'must rest on a verifiably real clinical foundation and adhere to established ethical frameworks for human subject research'. Also states the journal 'does not endorse or condone the unvalidated off-label use of medications for unapproved oncological indications'. Excerpt read from the PubMed abstract of the notice (DOI 10.21873/anticanres.18276). Superseded in part by the September update and the October retraction. Study type: other.